ArticleJournal of the anus, rectum and colon2025
Prediction of the Therapeutic Response to Neoadjuvant Chemotherapy for Rectal Cancer Using a Deep Learning Model.
Article in Journal of the anus, rectum and colon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Predicting the response to chemotherapy can lead to the optimization of neoadjuvant chemotherapy (NAC). The present study aimed to develop a non-invasive prediction model of therapeutic response to NAC for rectal cancer (RC). Methods: A dataset of the prechemotherapy computed tomography (CT) images of 57 patients from multiple institutions who underwent rectal surgery after three courses of S-1 and oxaliplatin (SOX) NAC for RC was collected. The therapeutic response to NAC was pathologically confirmed. It was then predicted whether they were pathologic responders or non-responders. Cases were divided into training, validation and test datasets. A CT patch-based predictive model was developed using a residual convolutional neural network and the predictive performance was evaluated. Binary logistic regression analysis of prechemotherapy clinical factors showed that none of the independent variables were significantly associated with the non-responders. Results: Among the 49 patients in the training and validation datasets, there were 21 (42.9%) and 28 (57.1%) responders and non-responders, respectively. A total of 3,857 patches were extracted from the 49 patients. In the validation dataset, the average sensitivity, specificity and accuracy was 97.3, 95.7 and 96.8%, respectively. Furthermore, the area under the receiver operating characteristic curve (AUC) was 0.994 (95% CI, 0.991-0.997; P<0.001). In the test dataset, which included 750 patches from 8 patients, the predictive model demonstrated high specificity (89.9%) and the AUC was 0.846 (95% CI, 0.817-0.875; P<0.001). Conclusions: The non-invasive deep learning model using prechemotherapy CT images exhibited high predictive performance in predicting the pathological therapeutic response to SOX NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.